For Q2 of 2026 a Class A investment in Laughing Water Capital returned approximately 39.8% net of all fees and expenses. Read ...
The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. | The ...
Indian pharma is entering its next growth phase as a new segment gains traction. We analyse four companies building this ...
Pfizer and Amgen both grew revenue last quarter at nearly the same pace, but the engines driving that growth point toward two very different futures in oncology. One company is collecting cash from ...
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced ...
GlobalData on MSN
MSD’s Keytruda-Padcev combo secures EC approval for MIBC
The approval is based on results from the KEYNOTE-905/EV-303 trial, conducted in partnership with Pfizer and Astellas.
US FDA approves Pfizer & Astellas’ Padcev plus Keytruda as neoadjuvant and adjuvant treatment for MIBC regardless of cisplatin eligibility: New York Monday, July 13, 2026, 13:00 ...
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to report second quarter results on July 31, with investors focused on the ...
Launching prescription medicines excellently – achieving optimal commercial performance that reflects a medicine’s value and ...
Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...
Discover 5 top Big Pharma stocks amid rising cancer, type 2 diabetes and IMIDs—dividend yields, earnings beats and why they ...
Redwire Corporation (NYSE: RDW), a global leader in aerospace and defense technology solutions, announced today it has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results